Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
- DOI
- 10.21203/rs.3.rs-2192036/v1
- Published
- 2022-11-07
- Container
- Not recorded
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 39/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- cautionPublication version: Identified as a preprint; peer review and later versions may change the record.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21203/rs.3.rs-2192036/v1,
title = {Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)},
author = {Watanabe K and Niikura N and Kikawa Y and Oba M and Kobayashi K and Tada H and Ozaki S and Toh U and Yamamoto Y and Tsuneizumi M and Okuno T and Iwakuma N and Takeshita T and Iwamoto T and Ishiguro H and Masuda N and Saji S.},
year = {2022},
doi = {10.21203/rs.3.rs-2192036/v1},
url = {https://doi.org/10.21203/rs.3.rs-2192036/v1}
}RIS
TY - JOUR TI - Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial) AU - Watanabe K AU - Niikura N AU - Kikawa Y AU - Oba M AU - Kobayashi K AU - Tada H AU - Ozaki S AU - Toh U AU - Yamamoto Y AU - Tsuneizumi M AU - Okuno T AU - Iwakuma N AU - Takeshita T AU - Iwamoto T AU - Ishiguro H AU - Masuda N AU - Saji S. PY - 2022 DO - 10.21203/rs.3.rs-2192036/v1 UR - https://doi.org/10.21203/rs.3.rs-2192036/v1 ER -
APA
K, W., N, N., Y, K., M, O., K, K., H, T., S, O., U, T., Y, Y., M, T., T, O., N, I., T, T., T, I., H, I., N, M., & S., S. (2022). Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). https://doi.org/10.21203/rs.3.rs-2192036/v1
Source records
- europe-pmc · retrieved 2026-09-26T22:13:33.189Z